Chloroquine diphosphate

Chloroquine diphosphate (CAS 50-63-5) is an antimalarial agent and inhibitor of TLR7 and TLR9, commonly used in biomedical research to modulate autophagic processes. On the cellular level, chloroquine diphosphate promotes autophagy through cell cycle arrest at the G1 phase, involving increased expression of p27 and p53 and decreased levels of CDK2 and cyclin D1. Additionally, chloroquine diphosphate enhances sensitivity of cancer cells toward chemotherapy and radiotherapy treatments by elevating autophagy and apoptotic responses. In vitro studies demonstrated dose-dependent activity, with reported IC50 values typically ranging from approximately 15 to 40 µM depending on cell types. This compound is widely utilized as an autophagy modulator and therapeutic adjuvant in tumor cell models.

References:
[1].  Gewirtz, D.A., An autophagic switch in the response of tumor cells to radiation and chemotherapy. Biochem Pharmacol, 2014. 90(3): p. 208-11.
[2].  Jiang, P.D., et al., Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother, 2010. 64(9): p. 609-14.
[3].  Choi, J.H., et al., Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. APMIS, 2012. 120(7): p. 597-604.
[4].  Zhou, Z.R., et al., Poly(ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells. Oncol Rep, 2013. 29(6): p. 2498-506.
[5].  Sasaki, K., et al., Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study. Anticancer Drugs, 2012. 23(7): p. 675-82.